A great advance in the treatment of all CD20 positive B-cell lymphoproliferative disorders has been achieved by the addition of anti-CD20 monoclonal antibody Rituximab to standard chemotherapy. As a consequence, Rituximab has also greatly expanded the treatment options for patients with chronic lymphocytic leukemia (CLL), a “mature” B-cell malignancy characterized by an increase in marrow and circulating neoplastic B-lymphocytes. Interestingly, several autoimmune disorders are also successfully treated with Rituximab.
Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia
D'ARENA, GIOVANNI;PATELLA, VINCENZO;DE FEO, Vincenzo;
2015-01-01
Abstract
A great advance in the treatment of all CD20 positive B-cell lymphoproliferative disorders has been achieved by the addition of anti-CD20 monoclonal antibody Rituximab to standard chemotherapy. As a consequence, Rituximab has also greatly expanded the treatment options for patients with chronic lymphocytic leukemia (CLL), a “mature” B-cell malignancy characterized by an increase in marrow and circulating neoplastic B-lymphocytes. Interestingly, several autoimmune disorders are also successfully treated with Rituximab.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
